-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Hold" by Analysts
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Hold" by Analysts
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) has been given a consensus recommendation of "Hold" by the six analysts that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.75.
Several equities analysts have issued reports on the company. Jefferies Financial Group lowered Forma Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $28.00 to $20.00 in a research note on Friday, September 2nd. HC Wainwright lowered Forma Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $53.00 to $20.00 in a research note on Friday, September 2nd. Oppenheimer lowered Forma Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 1st. Cantor Fitzgerald lowered Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 1st. Finally, Credit Suisse Group lowered Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 target price on the stock. in a research report on Friday, September 2nd.
Get Forma Therapeutics alerts:Hedge Funds Weigh In On Forma Therapeutics
A number of institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its holdings in Forma Therapeutics by 125.0% during the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after buying an additional 2,000 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Forma Therapeutics by 17,885.7% during the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after buying an additional 2,504 shares in the last quarter. Amalgamated Bank bought a new stake in Forma Therapeutics during the first quarter worth $38,000. US Bancorp DE grew its holdings in Forma Therapeutics by 282.5% during the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after buying an additional 3,206 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Forma Therapeutics by 56.3% during the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after buying an additional 3,670 shares in the last quarter. 87.39% of the stock is owned by institutional investors and hedge funds.
Forma Therapeutics Stock Performance
Shares of FMTX opened at $19.95 on Tuesday. Forma Therapeutics has a 52-week low of $4.95 and a 52-week high of $24.99. The business's 50 day moving average price is $14.79 and its two-hundred day moving average price is $10.07. The firm has a market cap of $954.61 million, a PE ratio of -4.99 and a beta of -0.31.About Forma Therapeutics
(Get Rating)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) has been given a consensus recommendation of "Hold" by the six analysts that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.75.
據Marketbeat報道,ForMA治療控股公司(納斯達克代碼:FMTX-GET評級)已被追蹤該公司的六位分析師一致給予“持有”的建議。五位投資分析師對該股的評級為持有建議,一位分析師對該公司發出了買入建議。在去年更新了對該股覆蓋範圍的分析師中,12個月的平均價格目標是20.75美元。
Several equities analysts have issued reports on the company. Jefferies Financial Group lowered Forma Therapeutics from a "buy" rating to a "hold" rating and dropped their price target for the company from $28.00 to $20.00 in a research note on Friday, September 2nd. HC Wainwright lowered Forma Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $53.00 to $20.00 in a research note on Friday, September 2nd. Oppenheimer lowered Forma Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 1st. Cantor Fitzgerald lowered Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 1st. Finally, Credit Suisse Group lowered Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 target price on the stock. in a research report on Friday, September 2nd.
幾位股票分析師已經發布了關於該公司的報告。傑富瑞金融集團在9月2日星期五的一份研究報告中將Forma Treeutics的評級從“買入”下調至“持有”,並將該公司的目標價從28.00美元下調至20.00美元。在9月2日星期五的一份研究報告中,HC Wainwright將Forma Treateutics的評級從“買入”下調至“中性”,並將該公司的目標價從53.00美元下調至20.00美元。奧本海默在9月1日星期四的一份研究報告中將Forma治療公司的評級從“跑贏大盤”下調至“市場表現”。坎託·菲茨傑拉德在9月1日星期四的一份研究報告中將Forma治療公司的評級從“增持”下調至“中性”。最後,瑞士信貸集團將Forma Treateutics的評級從表現優於大盤下調至中性,併為該股設定了20.00美元的目標價。在9月2日星期五的一份研究報告中。
Hedge Funds Weigh In On Forma Therapeutics
對衝基金對Forma Treeutics的看法
A number of institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its holdings in Forma Therapeutics by 125.0% during the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after buying an additional 2,000 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Forma Therapeutics by 17,885.7% during the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after buying an additional 2,504 shares in the last quarter. Amalgamated Bank bought a new stake in Forma Therapeutics during the first quarter worth $38,000. US Bancorp DE grew its holdings in Forma Therapeutics by 282.5% during the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after buying an additional 3,206 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Forma Therapeutics by 56.3% during the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after buying an additional 3,670 shares in the last quarter. 87.39% of the stock is owned by institutional investors and hedge funds.
多家機構投資者最近調整了對FMTX的持倉。第一季度,Quantbot Technologies LP對Forma Treateutics的持股增加了125.0%。Quantbot Technologies LP現在持有該公司3600股股票,價值3.3萬美元,上個季度又購買了2000股。Advisor Group Holdings Inc.在第一季度增持了Forma Treateutics 17885.7%的股份。Advisor Group Holdings Inc.現在持有該公司2,518股股票,價值33,000美元,上個季度又購買了2,504股。合併銀行在第一季度購買了Forma Treateutics價值3.8萬美元的新股份。第一季度,US Bancorp DE在Forma Treateutics的持股增加了282.5%。US Bancorp DE現在擁有4341股該公司股票,價值4萬美元,此前在上個季度又購買了3206股。最後,Legal&General Group Plc在第二季度增持了Forma Treateutics 56.3%的股份。Legal&General Group Plc現在擁有10,187股該公司股票,價值70,000美元,上個季度又購買了3,670股。87.39%的股票由機構投資者和對衝基金持有。
Forma Therapeutics Stock Performance
Forma治療公司股票表現
About Forma Therapeutics
關於Forma Treateutics
(Get Rating)
(獲取評級)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Forma治療控股公司是一家臨牀階段的生物製藥公司,專注於治療罕見血液疾病和癌症的新療法的開發和商業化。其待開發的核心產品包括FT-4202,這是治療鐮狀細胞疾病和其他血紅蛋白疾病的第一階段試驗;以及FT-7051,用於治療轉移性去勢抵抗前列腺癌。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免費獲取StockNews.com關於Forma治療(FMTX)的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 讓Paychex股票為您努力工作
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Forma治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Forma Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧